These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND Neurokinin
25 results:

  • 1. The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study.
    Alalikhan A; Ebrahimi S; Aliee A; Mirzavi F; Hashemy SI
    Med Oncol; 2024 Feb; 41(3):70. PubMed ID: 38340190
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. IFN-α/β-mediated NK2R expression is related to the malignancy of colon cancer cells.
    Xiang H; Toyoshima Y; Shen W; Wang X; Okada N; Kii S; Sugiyama K; Nagato T; Kobayashi H; Ikeo K; Hashimoto S; Tanino M; Taketomi A; Kitamura H
    Cancer Sci; 2022 Aug; 113(8):2513-2525. PubMed ID: 35561088
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The substance P/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells.
    Golestaneh M; Firoozrai M; Javid H; Hashemy SI
    Mol Biol Rep; 2022 Jun; 49(6):4893-4900. PubMed ID: 35429316
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Impact of the Oncology Care Model on Use of Supportive Care Medications During cancer Treatment.
    Brooks GA; Landrum MB; Kapadia NS; Liu PH; Wolf R; Riedel LE; Hsu VD; Jhatakia Parekh S; Simon C; Hassol A; Keating NL
    J Clin Oncol; 2022 Jun; 40(16):1763-1771. PubMed ID: 35213212
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
    Shimokawa M; Hayashi T; Nishimura J; Satoh T; Fukunaga M; Matsui R; Tsuji Y; Mizuki F; Kogawa T
    BMC Cancer; 2021 Oct; 21(1):1111. PubMed ID: 34656107
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in colorectal cancer.
    Shi Y; Wang X; Meng Y; Ma J; Zhang Q; Shao G; Wang L; Cheng X; Hong X; Wang Y; Yan Z; Cao Y; Kang J; Fu C
    Adv Sci (Weinh); 2021 Nov; 8(21):e2101936. PubMed ID: 34605226
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
    De Luca R; Volpe C; Mistretta O; Paci R; Ferrera G; Caputo V; Rosati G; Cicero G
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5310-5317. PubMed ID: 34486707
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Investigation of the Role of neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-
    Ghahremanloo A; Javid H; Afshari AR; Hashemy SI
    Biomed Res Int; 2021; 2021():1383878. PubMed ID: 34395609
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy-induced nausea and vomiting: A prospective cohort study.
    Park HS; Won HS; An HJ; Cho SS; Kim HH; Sun S; Ko YH; Shim BY
    Cancer Med; 2021 Feb; 10(3):1057-1065. PubMed ID: 33369184
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. 5HT
    Hayashi T; Shimokawa M; Matsuo K; Nishimura J; Iihara H; Nakano T; Egawa T
    Cancer Sci; 2021 Feb; 112(2):744-750. PubMed ID: 33274555
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301).
    Takei S; Ishibe A; Watanabe J; Watanabe K; Suwa Y; Suzuki S; Nakagawa K; Suwa H; Ota M; Ichikawa Y; Kunisaki C; Yamanaka T; Endo I
    Int J Colorectal Dis; 2020 Dec; 35(12):2323-2329. PubMed ID: 32860080
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer.
    Lorestani S; Ghahremanloo A; Jangjoo A; Abedi M; Hashemy SI
    Mol Biol Rep; 2020 May; 47(5):3469-3474. PubMed ID: 32277443
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
    Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
    Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Basic and translational research progress of gastrointestinal neuroendocrine neoplasmas].
    Song Y; Li X; Song T; Lin G; Chen Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1217-1221. PubMed ID: 27928788
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
    Okuyama A; Nakamura F; Higashi T
    JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
    Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
    Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.
    Isidro RA; Cruz ML; Isidro AA; Baez A; Arroyo A; González-Marqués WA; González-Keelan C; Torres EA; Appleyard CB
    World J Gastroenterol; 2015 Feb; 21(6):1749-58. PubMed ID: 25684939
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.
    Di Maio M; Bria E; Banna GL; Puglisi F; Garassino MC; Lorusso D; Perrone F
    Anticancer Drugs; 2013 Feb; 24(2):99-111. PubMed ID: 23165435
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer.
    Gillespie E; Leeman SE; Watts LA; Coukos JA; O'Brien MJ; Cerda SR; Farraye FA; Stucchi AF; Becker JM
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17420-5. PubMed ID: 21969570
    [TBL] [Abstract] [Full Text] [Related]  

    [Next]

    of 2.